Intercept Pharmaceuticals reported $88.79M in Sales Revenues for its fiscal quarter ending in September of 2023.



Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.4B 300M Sep/2026
Arrowhead Research USD 450.82M 375.59M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026